Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C12H19NO.ClH |
Molecular Weight | 229.746 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCN(C)[C@@H](C)[C@H](O)C1=CC=CC=C1
InChI
InChIKey=WRONACHIHQGZSD-JGAZGGJJSA-N
InChI=1S/C12H19NO.ClH/c1-4-13(3)10(2)12(14)11-8-6-5-7-9-11;/h5-10,12,14H,4H2,1-3H3;1H/t10-,12-;/m0./s1
Etafedrine, a sympathomimetic agent that acts on the sympathetic receptors of the bronchial tree relaxing spasm in a manner similar to that of ephedrine, is a bronchodilator and a selective β2-adrenoreceptor agonist. Contraction of the guinea pig tracheal chain by acetylcholine or histamine was antagonized by etafedrine with a higher potency then ephedrine but with a lower potency than epinephrine (adrenaline). Etafedrine did not increase heart rate or force of contraction in guinea pig atria. Unlike ephedrine and tyramine, etafedrine did not induce the release of noradrenaline as was demonstrated in vitro in the perfused rabbit heart and instead acted as a selective β2 adrenoreceptor agonist. Etafedrine also belongs to the family of medications called decongestants. It works by narrowing blood vessels in the nasal passages, helping to relieve nasal stuffiness. Etafedrine has been used in pharmaceutical compositions, such as NETHAPRIN Expectorant, Nethaprin Dospan and Dalmacol, useful in the treatment of asthma and other respiratory disorders including chronic bronchitis.
Originator
Sources: http://www.trademarkia.com/nethaprin-72238669.html
Curator's Comment: Etafedrine was registered under the trade mark NETHAPRIN in 9/20/1966 as an antiasthmatic medicine.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P07550|||Q53GA6|||Q9UCZ3 Gene ID: 154.0 Gene Symbol: ADRB2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/4039586 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | NETHAPRIN Expectorant Approved UseConditions characterized by bronchial congestion and bronchospasm when an expectorant and bronchodilator action is desired, such as in acute bronchitis, acute episodes of chronic bronchitis and bronchial asthma. |
|||
Palliative | NETHAPRIN Expectorant Approved UseConditions characterized by bronchial congestion and bronchospasm when an expectorant and bronchodilator action is desired, such as in acute bronchitis, acute episodes of chronic bronchitis and bronchial asthma. |
|||
Palliative | Dalmacol Approved UseTo control cough associated with inflammation of the mouth and throat that is not helped by cough medications that are less strong. |
|||
Palliative | Nethaprin Dospan Approved UseUsed for Bronchodilator, Insomnia, Allergic Reactions, Morning Sickness In Pregnant Women, Cold, Allergic Symptoms and other symptoms |
|||
Palliative | Nethaprin Dospan Approved UseUsed for Bronchodilator, Insomnia, Allergic Reactions, Morning Sickness In Pregnant Women, Cold, Allergic Symptoms and other symptoms |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.1 μg/mL |
24 mg single, oral dose: 24 mg route of administration: Oral experiment type: SINGLE co-administered: |
ETAFEDRINE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6 h |
24 mg single, oral dose: 24 mg route of administration: Oral experiment type: SINGLE co-administered: |
ETAFEDRINE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
Sample Use Guides
Dalmacol (each mL contains hydrocodone bitartrate 0.33 mg, etafedrine HCl 3.33 mg, sodium citrate 40 mg, and doxylamine succinate 1.2 mg) the recommended dose is 5 mL (1 teaspoonful) every 3 to 5 hours as needed, but not more than 30 mL in any 24-hour period for adults. For children 6 to 12 years of age, the recommended dose is 2.5 mL to 5 mL every 3 to 5 hours as needed, but not more than 15 mL in any 24-hour period. For children 1 to 6 years of age, the recommended dose is 1.25 mL to 2.5 mL every 3 to 5 hours as needed, but not more than 3 doses in any 24-hour period.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4039586
Effects of (-)-N-ethylephedrine (etafedrine) were studied on the tracheal chain preparation and the atria of the guinea pig and on the rabbit perfused heart. Contraction of the tracheal chain by acetylcholine or histamine was antagonized by etafedrine. Propranolol (5 X 10(-7) M) completely antagonized the bronchodilator effect of 10(-4) M etafedrine on the acetylcholine-evoked contraction. Etafedrine up to 3 X 10(-4) M did not increase heart rate or force of contraction in guinea pig atria. In contrast to tyramine and ephedrine (both 10(-5) M), etafedrine (10(-4) M) failed to release 3H-norepinephrine (noradrenaline) in the perfused rabbit heart. Moreover, the concentration-dependent positive chronotropic and inotropic effects of norepinephrine in isolated atria were slightly, but not significantly enhanced by etafedrine.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29747
Created by
admin on Fri Dec 15 15:10:47 GMT 2023 , Edited by admin on Fri Dec 15 15:10:47 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID90967476
Created by
admin on Fri Dec 15 15:10:47 GMT 2023 , Edited by admin on Fri Dec 15 15:10:47 GMT 2023
|
PRIMARY | |||
|
100000087276
Created by
admin on Fri Dec 15 15:10:47 GMT 2023 , Edited by admin on Fri Dec 15 15:10:47 GMT 2023
|
PRIMARY | |||
|
208-476-3
Created by
admin on Fri Dec 15 15:10:47 GMT 2023 , Edited by admin on Fri Dec 15 15:10:47 GMT 2023
|
PRIMARY | |||
|
5591-29-7
Created by
admin on Fri Dec 15 15:10:47 GMT 2023 , Edited by admin on Fri Dec 15 15:10:47 GMT 2023
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
C75032
Created by
admin on Fri Dec 15 15:10:47 GMT 2023 , Edited by admin on Fri Dec 15 15:10:47 GMT 2023
|
PRIMARY | |||
|
227-000-5
Created by
admin on Fri Dec 15 15:10:47 GMT 2023 , Edited by admin on Fri Dec 15 15:10:47 GMT 2023
|
ALTERNATIVE | |||
|
Y134VQ304Y
Created by
admin on Fri Dec 15 15:10:47 GMT 2023 , Edited by admin on Fri Dec 15 15:10:47 GMT 2023
|
PRIMARY | |||
|
530-35-8
Created by
admin on Fri Dec 15 15:10:47 GMT 2023 , Edited by admin on Fri Dec 15 15:10:47 GMT 2023
|
PRIMARY | |||
|
CHEMBL2110926
Created by
admin on Fri Dec 15 15:10:47 GMT 2023 , Edited by admin on Fri Dec 15 15:10:47 GMT 2023
|
PRIMARY | |||
|
SUB01979MIG
Created by
admin on Fri Dec 15 15:10:47 GMT 2023 , Edited by admin on Fri Dec 15 15:10:47 GMT 2023
|
PRIMARY | |||
|
C007636
Created by
admin on Fri Dec 15 15:10:47 GMT 2023 , Edited by admin on Fri Dec 15 15:10:47 GMT 2023
|
PRIMARY | |||
|
DBSALT001778
Created by
admin on Fri Dec 15 15:10:47 GMT 2023 , Edited by admin on Fri Dec 15 15:10:47 GMT 2023
|
PRIMARY | |||
|
m5034
Created by
admin on Fri Dec 15 15:10:47 GMT 2023 , Edited by admin on Fri Dec 15 15:10:47 GMT 2023
|
PRIMARY | Merck Index | ||
|
76964725
Created by
admin on Fri Dec 15 15:10:47 GMT 2023 , Edited by admin on Fri Dec 15 15:10:47 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD